MC2 Therapeutics Announces Collaboration Agreement with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA® Cream, in the US

POSTED: August 24, 2020

• Collaboration accelerates a Q1 2021 comprehensive launch of MC2’s WYNZORA^® Cream to patients with plaque psoriasis in the US
• WYNZORA^® Cream is the first drug based on PAD^TM Technology – providing ...

  READ FULL ARTICLE >

MC2 Therapeutics Announces U.S. Food and Drug Administration Approval of Wynzora® Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%) for Adults with Plaque Psoriasis

POSTED: July 22, 2020

Copenhagen, July 22^nd, 2020 – MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard of topical therapies for chronic inflammatory conditions, announced today that the U.S. Food and ...

READ FULL ARTICLE >

MC2 Therapeutics Announces Submission of Marketing Authorization Application in EU for Wynzora® Cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone (as dipropionate)

POSTED: July 16, 2020

Copenhagen, July 16^th, 2020 – MC2 Therapeutics, a commercial stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions, today announced the submission of its Marketing Authorization Application (MAA) ...

READ FULL ARTICLE >